<DOC>
	<DOCNO>NCT00041262</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know regimen combination chemotherapy effective treating esophageal cancer . PURPOSE : Randomized phase III trial compare effectiveness two regimen combination chemotherapy treat patient undergo surgery esophageal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Esophageal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare survival quality life patient resectable adenocarcinoma esophagus treat prior surgery standard chemotherapy comprise cisplatin fluorouracil versus prolong infusional chemotherapy comprise cisplatin , epirubicin , fluorouracil . OUTLINE : This randomize , multicenter study . Patients randomize one two treatment arm . - Arm I ( Standard chemotherapy ) : Patients receive cisplatin IV 4 hour day 1-4 fluorouracil IV continuously day 1-4 . Treatment repeat every 21 day 2 course absence disease progression unacceptable toxicity . - Arm II ( Infusional chemotherapy ) : Patients receive cisplatin IV 4 hour day 1 , epirubicin IV day 1 , fluorouracil IV continuously . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients undergo surgery 4-6 week last dose fluorouracil arm I anytime fluorouracil infusion complete arm II . Quality life assess baseline , immediately start last course chemotherapy , immediately surgery , 6 week post-operatively , 6 , 9 , 12 , 18 , 24 month randomization . Patients follow every 3 month 1 year , every 6 month 5 year , annually thereafter . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : Approximately 1,300 patient ( 650 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma esophagus type 1 2 tumor gastroesophageal junction Stage IIB great spiral multislice CT scan endoscopic ultrasound Amenable primary surgery curative intent No paraaortic/celiac lymphadenopathy great 1 cm CT scan and/or great 6 mm endoscopic ultrasound No disease invade airway , aorta , pericardium , lung No liver , lung , distant metastasis PATIENT CHARACTERISTICS : Age : Not specify Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : WBC great 3,000/mm3 Platelet count great 100,000/mm3 Hepatic : Liver function test great 1.5 time normal Renal : Glomerular filtration rate great 60 mL/min Cardiovascular : Ejection fraction great 50 % OR Normal echocardiograph Pulmonary : FEV1 great 1.5 L Other : Not pregnant nursing No prior primary malignancy No significant medical condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>stage IIB esophageal cancer</keyword>
	<keyword>stage IIIA esophageal cancer</keyword>
	<keyword>stage IIIB esophageal cancer</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>